

Yohimbine Depresses Excitatory Transmission in BNST and Impairs Extinction of Cocaine Place Preference Through Orexin-Dependent, Norepinephrine-Independent Processes

Kelly L Conrad¹, Adeola R Davis², Yuval Silberman¹, Douglas J Sheffler^{3,4}, Angela D Shields¹, Sam A Saleh³, Namita Sen^{5,6,7}, Heinrich JG Matthies², Jonathan A Javitch^{5,6,7}, Craig W Lindsley^{3,4} and Danny G Winder^{*,1,2,8,9}

¹Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN, USA; ²Department of Center for Molecular Neuroscience, Vanderbilt University School of Medicine, Nashville, TN, USA; ³Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, USA; ⁴Department of Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine, Nashville, TN, USA; ⁵Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY, USA;

⁶Department of Pharmacology, College of Physicians and Surgeons, Columbia University, New York, NY, USA; ⁷Department of Pharmacology, Center for Molecular Recognition, College of Physicians and Surgeons, Columbia University, New York, NY, USA; ⁸Kennedy Center for Research on Human Development, Vanderbilt University School of Medicine, Nashville, TN, USA; ⁹Vanderbilt Brain Institute, Nashville, TN, USA

The alpha2 adrenergic receptor (α_2 -AR) antagonist yohimbine is a widely used tool for the study of anxiogenesis and stress-induced drug-seeking behavior. We previously demonstrated that yohimbine paradoxically depresses excitatory transmission in the bed nucleus of the stria terminalis (BNST), a region critical to the integration of stress and reward pathways, and produces an impairment of extinction of cocaine-conditioned place preference (cocaine-CPP) independent of α_2 -AR signaling. Recent studies show yohimbine-induced drug-seeking behavior is attenuated by orexin receptor 1 (OX₁R) antagonists. Moreover, yohimbine-induced cocaine-seeking behavior is BNST-dependent. Here, we investigated yohimbine-orexin interactions. Our results demonstrate yohimbine-induced depression of excitatory transmission in the BNST is unaffected by alpha1-AR and corticotropin-releasing factor receptor-1 (CRFR₁) antagonists, but is (1) blocked by OX₁R antagonists and (2) absent in brain slices from orexin knockout mice. Although the actions of yohimbine were not mimicked by the norepinephrine transporter blocker reboxetine, they were by exogenously applied orexin A. We find that, as with yohimbine, orexin A depression of excitatory transmission in BNST is OX₁R-dependent. Finally, we find these *ex vivo* effects are paralleled *in vivo*, as yohimbine-induced impairment of cocaine-CPP extinction is blocked by a systemically administered OX₁R antagonist. These data highlight a new mechanism for orexin on excitatory anxiety circuits and demonstrate that some of the actions of yohimbine may be directly dependent upon orexin signaling and independent of norepinephrine and CRF in the BNST.

Neuropsychopharmacology (2012) **37**, 2253–2266; doi:10.1038/npp.2012.76; published online 23 May 2012

Keywords: norepinephrine; orexin; plasticity; reward; stress; yohimbine

INTRODUCTION

The widely used pharmacological stressor yohimbine induces relapse to drug- and alcohol-seeking behavior (Shaham *et al*, 2000; Shalev *et al*, 2010). In abstinent drug-dependent subjects, yohimbine increases anxiety (McDougle *et al*, 1994) and drug craving (Stine *et al*, 2002). Yohimbine is thought to act primarily via its inhibition of presynaptic noradrenergic alpha2 adrenergic receptor (α_2 -ARs), thereby

increasing norepinephrine levels (Abercrombie *et al*, 1988; Aghajanian and VanderMaelen, 1982; Starke, 2001). In addition to research using yohimbine as a pharmacological stressor to induce illicit drug- and alcohol-reinstatement (Shaham *et al*, 2000; Shalev *et al*, 2010), recent studies demonstrate yohimbine impairs extinction of cocaine-conditioned place preference (cocaine-CPP) and self-administration (Davis *et al*, 2008; Kupferschmidt *et al*, 2009; Marinelli *et al*, 2007).

The bed nucleus of the stria terminalis (BNST), a key site for the integration of stress and reward processing, is a critical region mediating the effects of stressors on cocaine-seeking behavior (Buffalari and See, 2010; Erb *et al*, 2001; Leri *et al*, 2002). In particular, the BNST is critical for yohimbine-induced reinstatement of drug-seeking behavior (Brown *et al*, 2009; Buffalari and See, 2010). Yohimbine depresses

*Correspondence: Dr DG Winder, Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN 37232, USA, Tel: +1 615 322 1144, Fax: +1 615 322 1462, E-mail: danny.winder@vanderbilt.edu

Received 13 March 2012; revised 18 April 2012; accepted 19 April 2012

excitatory transmission in the adult dorsal BNST (Davis *et al*, 2008). This finding is paradoxical given that α_2 -AR agonists produce similar actions (Davis *et al*, 2008; Shields *et al*, 2009). Further, the effects of yohimbine on both excitatory transmission and extinction of cocaine-CPP are intact in α_{2A} -AR knockout mice and not fully mimicked by the α_2 -AR antagonist atipamezole, suggesting that they are mediated by targets other than α_2 -ARs (Davis *et al*, 2008).

Yohimbine-induced reinstatement of cocaine-seeking behavior requires orexin 1 receptor (OX₁R) activity (Buffalari and See, 2010; Zhou *et al*, 2011). The orexin system was first described in the late 1990s, when the orexin neuropeptides were shown to be important in feeding and arousal-related behaviors (de Lecea *et al*, 1998; Sakurai *et al*, 1998). Since then, studies have demonstrated an important role for the orexin system in anxiety and reward-related behaviors (Boutrel *et al*, 2005; Dayas *et al*, 2008; Espana *et al*, 2010; Harris *et al*, 2005; Johnson *et al*, 2010; Lawrence *et al*, 2006; Richards *et al*, 2008; Zhou *et al*, 2011). The BNST receives dense orexinergic inputs (Baldo *et al*, 2003) and has a high density of OX₁R mRNA and protein expression (Hervieu *et al*, 2001; Marcus *et al*, 2001). Further, anxiety-like behaviors in rodents are dependent on BNST OX₁R signaling (Johnson *et al*, 2010).

Here, we investigated the role of OxRs in the actions of yohimbine on excitatory transmission in the BNST, and on extinction of cocaine-CPP. These studies reveal that yohimbine recruits an OX₁R-dependent depression of excitatory transmission in BNST, and that a systemically administered OX₁R antagonist blocks yohimbine-mediated impairment of extinction of cocaine-CPP. Taken together, our results suggest yohimbine acts in a norepinephrine-independent manner to recruit orexin signaling and impact excitatory transmission in the adult BNST, demonstrating a novel role for orexin A as an inhibitory neuropeptide on excitatory input in anxiety and reward circuits. Finally, we identify a role for orexin in mediating the effects of the stressor yohimbine on cocaine extinction.

SUBJECTS AND METHODS

Subjects

Experiments on C57BL/6J mice were conducted using males aged 8–12 weeks obtained from the Jackson Laboratory (Bar Harbor, ME). Male α_{2A} -AR KO mice were generated as previously described (Altman *et al*, 1999) and backcrossed onto a C57BL/6J genetic background for a minimum of eight generations. Mice were housed on a 12-h light/dark cycle in groups of two to five with *ad libitum* access to food and water. Testing commenced at least 1 week after acclimation to the facilities. All procedures were approved by the Vanderbilt University Animal Care and Use Committees and were in accordance with the Animal Welfare Act. The number of mice used is reported in the figure legends.

Mouse Drug Treatment

All drugs were administered intraperitoneally (i.p.) in a volume of 10 ml/kg body weight. For the cocaine-CPP

experiments: vehicle (0.9% sterile saline) and cocaine (20 mg/kg; i.p.) in vehicle were administered immediately before placement in the CPP apparatus.

For the cocaine-CPP extinction experiments: yohimbine in distilled H₂O (5 mg/kg; i.p.; 30 min prior) or vehicle (30 min prior) or SB-334867 (15 mg/kg; i.p. 1 h prior) in 1% (w/v) (2-hydroxypropyl)- β -cyclodextrin/10% dimethyl sulfoxide (DMSO) in sterile water (termed DMSO-vehicle; 1 h prior) were administered for extinction sessions 1–5. SB-334867 has been found to reach peak plasma and brain concentrations at 30 min post injection and maintains good exposure for up to 4 h (Porter *et al*, 2001). The dose of 5 mg/kg yohimbine was selected based on previous reports that this dose increases plasma corticosterone levels (Banihashemi and Rinaman, 2006). Moreover, 5 mg/kg but not 1 mg/kg yohimbine induces Fos expression in the lateral BNST (Myers *et al*, 2005). Finally, other studies in C57BL/6J mice (Cain *et al*, 2004; Hefner *et al*, 2008), as well as a previous study from our lab (Davis *et al*, 2008) have found the 5 mg/kg dose effective at altering fear and anxiety-related behaviors.

Cocaine-CPP and Extinction

The CPP and extinction design used here was described in detail previously (Davis *et al*, 2008). Briefly, the two chamber place preference apparatus consists of a box insert that slides into the open-field chamber (Med Associates; St Albans, VT). The paradigm consisted of a pre-test (day 1) and post-test (day 8) in which mice were given an intraperitoneal, (i.p.) saline injection and allowed unrestricted access to the contextually distinct mesh and bar-floor compartments. During conditioning, mice were given an i.p. saline injection and restricted to the mesh-floor compartment (days 2, 4, and 6) and an i.p. cocaine injection (20 mg/kg) and restricted to the bar-floor compartment (days 3, 5, and 7). All sessions were for 15 min.

The day following the post-test, extinction sessions began. Extinction sessions were the same as the preference session (access to both compartments) and were placed in one of the following four groups (time injection given before extinction session): SB-334867 (1 h)–vehicle (30 min), DMSO-vehicle (1 h)–yohimbine (30 min), DMSO-vehicle (1 h)–vehicle (30 min), and SB-334867 (1 h)–yohimbine (30 min). Immediately before each session, all mice were given an i.p. saline injection. Time spent in each compartment and the distance traveled was monitored throughout every session.

The data are presented as percent (%) of pre-test preference in order to convey the magnitude of the change in preference more clearly and for statistical analysis purposes among many groups.

Calcium Mobilization Assay

Human Embryonic Kidney (HEK-EM4) cells expressing the OX₁R were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS), 20 mM HEPES (pH 7.3), 2 mM L-glutamine, 1 \times antibiotic/antimycotic, and 100 μ g/ml Zeocin. HEK-293 cell lines co-expressing rat mGluR₂ and G-protein-coupled inwardly rectifying potassium (GIRK) channels (for additional

information, see Jin *et al*, 2010; Niswender *et al*, 2008) were grown in growth media containing 45% DMEM, 45% Ham's F12, 10% FBS, 20 mM HEPES (pH 7.3), 1 mM sodium pyruvate, 2 mM L-glutamine, 1 × antibiotic/antimycotic, 1 × non-essential amino acids, 700 µg/ml G418 (Mediatech, Inc., Herndon, VA), and 0.6 µg/ml puromycin dihydrochloride (Sigma-Aldrich, St Louis, MO) at 37 °C in the presence of 5% CO₂. All cell culture reagents were purchased from Invitrogen (Carlsbad, CA). The cells were plated in non-coated (HEK-EM4) or poly-D-lysine-pretreated (HEK-293) 96-well black-walled, clear bottom plates (Corning Life Sciences, Lowell, MA) at ~45 000 cells/well in growth media. Twenty-four hours later, 50 µl of calcium assay buffer (Hanks' balanced salt solution (HBSS; Invitrogen, Carlsbad, CA), 20 mM HEPES, 2.5 mM probenecid (Sigma, St Louis, MO), pH 7.4) containing 2 µM Fluo-4 (Invitrogen) was added into each well and the cells were incubated for 1 h at room temperature in the dark. The cells were washed with assay buffer and then incubated in with either 80 µl (Figure 4a and c) or 40 µl (Figure 4b) of assay buffer for 10 min at room temperature in the dark. Compounds were dissolved in the assay buffer, and the responses were recorded on a FLEXstation benchtop scanning fluorometer (Molecular Devices, Sunnyvale, CA) at room temperature, with the settings of 485 nm for excitation and 525 nm for emission. For Figures 6a and c, 20 µl of a 5 × compound was added at the 20-s time point and the fluorescence was monitored for a total of 240 s. For Figure 6b, 40 µl of 2 × SB-334867 was added at the 20 s time point, followed by addition of 5 × compound at the 180 s time point and the fluorescence was monitored for a total of 240 s. Maximal responses were observed with ~1 µM orexin A in orexin 1 receptor expressing cells and with 100 µM ATP in mGluR₂-expressing cells. Thus, in each experiment the results are expressed as a percentage of the response obtained with 1 µM orexin A, or EC80 orexin A (300 nM) or 100 µM ATP and are described as percentage of activation. Prism software (GraphPad Software Inc., San Diego, CA) was used to plot fluorescence intensities and to calculate the EC80 values.

Ex Vivo BNST Electrophysiology

Brain slice preparation. Brain slices from the dorsal anterolateral (dBNST) were prepared as previously described (Egli *et al*, 2005; Weitlauf *et al*, 2004). Briefly, male C57Bl6/j mice (8–12 weeks old, Jackson Laboratories) were retrieved from the colony and allowed to rest in sound attenuating boxes for a minimum of 1 h, after which they were decapitated under anesthesia (Isoflurane). The brains were quickly removed and placed in ice-cold artificial cerebro-spinal fluid (ACSF) (in mM: 124 NaCl, 4.4 KCl, 2 CaCl₂, 1.2 MgSO₄, 1 NaH₂PO₄, 10 glucose, and 26 NaHCO₃). Slices of 300 µm thickness were prepared using a vibratome (Leica). BNST slices containing anterior portions of BNST (bregma 0.26 mm to 0.02 mm) (Franklin and Paxinos, 1997) were identified using the internal capsule, anterior commissure, fornix, and stria terminalis as landmarks. Following slicing, hemisected slices were placed in an interface chamber (field recordings) or a holding chamber prior to transfer to a submerged perfusion chamber (whole-cell recordings) and were continuously perfused with oxygenated (95% O₂/5% CO₂) and heated (~28 °C) ACSF at a rate

of 2 ml/min. Slices were allowed to equilibrate in normal ACSF for 1 h before experiments began. 1–3 hemisected slices were used per animal.

Extracellular field recordings. Low-resistance (2–3 MΩ) extracellular electrodes were pulled with borosilicate glass on a Flaming-Brown Micropipette Puller (Sutter) and were filled with ACSF. Following dissection, slices were immediately placed in the interface chamber and allowed a minimum 60 min recovery period. Stimulating electrodes consisted of twisted, insulated nichrome bipolar wire. Stimulating electrodes were placed on the dorsal anterolateral BNST (dBNST) border of the internal capsule approximately 200–500 µm dorsal to the anterior commissure. To isolate excitatory transmission, all recordings were conducted in the presence of the GABA_A receptor antagonist, picrotoxin (25 µM). Field potential responses were evoked at a frequency of 0.05 Hz using a stimulus range of 5–15 V at a duration of 100–150 µs. Baseline responses (60% of maximum evoked responses) were recorded for a minimum of 20 min before drug application. Experiments in which the N1 (Figure 1b) changed by >20% were discarded.

Whole-cell patch-clamp recordings. Whole-cell recordings were performed as previously reported (Grueter and Winder, 2005; Kash and Winder, 2006). dBNST neurons were visualized and recorded via standard IR-DIC methods. Recording electrodes (4–6 MΩ) were filled with the following for experiments examining excitatory transmission (in mM): 117 Cs gluconate, 20 HEPES, 0.4 EGTA, 5 TEA, 2 MgCl, 4 Na₂ATP, 0.3, Na₂GTP (pH 7.2–7.4, Osm. 270–290). EPSCs of 100–250 pA were recorded at a frequency of 0.1 Hz while voltage-clamped at –70 mV in the presence of the GABA_A receptor antagonist, picrotoxin (25 µM). After whole-cell configuration was achieved, cells were allowed to equilibrate a minimum of 5 min before baseline recordings were started. For experiments in which the effects of antagonists were determined, the antagonist was applied for at least 15 min before application of the agonist and remained on for the duration of the experiment. Access resistance, input resistance, and holding current were monitored continuously throughout the duration of the experiments. Recordings in which access resistance changed by more than 20% were excluded from analysis. Following an 8–10 min baseline period, 2 µM SB-334867, 1 µM JNJ-10397049, 100 nM orexin A or 100 nM reboxetine was bath applied for 35 (SB-334867 and JNJ-10397049) 10 (reboxetine) or 20 (orexin A) min. Baseline values were calculated as an average of 3 min directly before agonist application. Recorded data was analyzed via Clampfit 10.2 (Molecular Devices). Both the % coefficient of variation (CV) and paired-pulse ratio (PPR) were examined to assess alterations in presynaptic release probability. Paired pulses with a 70 ms interstimulus interval were given every 20 s. The PPR was the ratio of averaged amplitude of the second EPSC (EPSC2) to that of the first EPSC (EPSC1).

Drugs

The following drugs were used for experiments: cocaine hydrochloride (National Institute on Drug Abuse, Bethesda, MD), SB-334867, 1-(2-methylbenzoxazol-6-yl)-3-[1,5]naphthyridin-4-yl urea hydrochloride; Tocris, Ellisville,




Figure 1 Norepinephrine and corticotrophin releasing factor (CRF) receptor 1 (CRFR₁) antagonists do not block yohimbine-induced depression of excitatory transmission in the dorsal anterolateral bed nucleus of the stria terminalis (dBNST). Extracellular field potential and whole-cell patch-clamp recordings of excitatory transmission in the dBNST: (a) left, diagram of coronal section containing the dBNST and demonstrating placement of stimulating and recording electrodes during electrophysiological recordings; right, a representative extracellular field potential recording trace depicting the TTX-sensitive N1 downward deflection and CNQX-sensitive N2 downward deflection. (b) 30 μ M yohimbine inset: corresponding N1; six slices recorded from five mice. (c) 30 μ M yohimbine in the presence of 10 μ M prazosin; six slices recorded from four mice. (d) 100 nM Reboxetine; six slices recorded from four mice. (e) 30 μ M yohimbine in the presence of 5 μ M NBI-27914; six slices recorded from five mice. (f) Summary of 86–90 min for yohimbine, prazosin + yohimbine, Reboxetine, NBI-27914 + yohimbine. Data are represented as mean \pm SEM, * p < 0.05, n = 5–6 slices per group.

Missouri), NBI-27914 (Sigma-Aldrich, St Louis, MO), yohimbine HCl (Sigma-Aldrich), methoxamine hydrochloride (Sigma-Aldrich), prazosin (Tocris), ATP (Sigma-Aldrich), carbachol (Sigma-Aldrich), orexin A (Ascent Scientific, Princeton, NJ), JNJ-10397047 and 2-[4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl]-quinazoline (MTBDQ; C Lindsley, Vanderbilt University), reboxetine (Tocris) and picrotoxin (Sigma-Aldrich). For the electrophysiology experiments, drugs were bath-applied at final concentrations, which are noted in the experimental design. DMSO is the solvent used for picrotoxin, NBI-27914, JNJ-10397047, prazosin, MTBDQ, orexin A, and SB-334867 in which the maximum final concentration of DMSO was 0.02% by volume. Methoxamine and yohimbine were dissolved in ddH₂O. Reboxetine was dissolved in 0.9% saline.

Statistical Analysis

When determining whether a drug had a significant effect, or mice displayed a significant difference between their expressed pre- and post-test preference for the cocaine-paired chamber, a paired Student's *t*-test was used to compare the baseline value (or pre-test preference) to the drug effect value (or post-test preference). Unpaired Student's *t*-test was used for determining effects between two separate experimental conditions (eg, post-test preference for the cocaine paired chamber between α_{2A} -AR-WT and KO mice). When comparing effects across more than two drug application experiments, a one-way analysis of

variance (ANOVA) was used. For extinction of cocaine-CPP experiments, a two-way ANOVA repeated measures (RM) was used. Student Newman Keuls or Holmes-Sidak multiple comparison *post hoc* test were used; if equal variance criteria were not met, the Games-Howell *post hoc* test was used.

RESULTS

Norepinephrine and Corticotrophin Releasing Factor (CRF) Receptor 1 (CRFR₁) Antagonists Do Not Block Yohimbine-induced Depression of Excitatory Transmission in the dBNST

A representative depiction of the location for all electrophysiological recordings of our stimulating and recording electrodes in slices containing the dBNST is presented in Figure 1a (left) and a representative extracellular field potential recording trace depicting the TTX-sensitive N1 (used to monitor slice health) downward deflection and CNQX-sensitive N2 downward deflection (Figure 1a; right, boxed inset). Extracellular field potential recordings from the dBNST revealed that a 30 min bath application of 30 μ M yohimbine resulted in a depression of excitatory transmission ($58.3 \pm 6.9\%$ of baseline in 86–90 min, $t_5 = 4.507$, $p = 0.004$, $n = 6$ slices from five mice, Figure 1b), similar to our previous report (Davis *et al*, 2008) and the N1 was unaffected in these recordings (inset; Figure 1b). We previously demonstrated that (a) this effect is not fully mimicked by the more selective α_2 -AR antagonist

atipamezole, and was not disrupted in slices obtained from α_{2A} -AR KO mice (Davis *et al*, 2008). As multiple actions of norepinephrine are disrupted in the BNST of these mice (Egli *et al*, 2005; McElligott *et al*, 2010), these data suggest that the actions of yohimbine on excitatory transmission are not likely mediated by α_2 -AR binding, or other norepinephrine dependent processes. It has recently been reported that the α_1 -AR antagonist prazosin can block yohimbine-induced drug-seeking behavior (Le *et al*, 2011). Thus, to further explore this issue, we assessed the ability of prazosin to block the depressant effects of yohimbine on excitatory transmission in the BNST. A 30 min application of 30 μ M yohimbine in the presence of 10 μ M prazosin depressed excitatory transmission ($59.3 \pm 3.9\%$ of baseline in 86–90 min, $t_5 = 11.52$, $*p < 0.001$, $n = 6$ slices from four mice, Figure 1c) in a manner that was not significantly different from that elicited by yohimbine alone (yohimbine in the presence of 10 μ M prazosin compared with 30 μ M yohimbine: $F_{3,18} = 0.1$, $p = \text{n.s.}$, Figure 1f). Finally, we assessed whether the norepinephrine transporter blocker reboxetine (100 nM), by elevating norepinephrine levels, could mimic the actions of yohimbine. Thus, if the available pool of synaptic norepinephrine in a deafferented slice is dynamic enough to be regulated by autoreceptors and produce the depressant effect elicited by yohimbine on excitatory transmission, we reasoned that reboxetine should mimic this effect. Utilizing whole-cell patch clamp recordings, a 10 min application of 100 nM reboxetine had no effect (96.8% of baseline in 25–30 min, $t_5 = 0.8$; $p = \text{n.s.}$, $n = 6$ slices from four mice, Figure 1d) on excitatory transmission in our experiments, as would be predicted in a deafferented slice where noradrenergic inputs are severed. These results suggest that modulation of extracellular norepinephrine levels is unlikely to contribute to the depressant effects of yohimbine on excitatory transmission in the dlBNST.

Given the anxiogenic effect of yohimbine and the presence of CRF neurons and terminals in the BNST (Champagne *et al*, 1998), we next assessed if CRFR₁ may be the target for the depressant effects of yohimbine on excitatory transmission. A 30 min application of yohimbine in the presence of the CRFR₁ antagonist, NBI-27914, elicited a significant depression on excitatory transmission ($63.2 \pm 6.7\%$ of baseline, $t_5 = 6.5$, $*p = 0.0013$, $n = 6$ slices from five mice, Figure 1e and f), demonstrating that CRFR₁ does not mediate the yohimbine-induced depression of excitatory transmission in the BNST.

Orexin Receptor (OxR) Antagonists Block Yohimbine-induced Depression of Excitatory Transmission in the dlBNST

Orexin A has been implicated in anxiety and reward-related behaviors (Buffalari and See, 2010; Dayas *et al*, 2008; Espana *et al*, 2010; Harris *et al*, 2005; Johnson *et al*, 2010; Lawrence *et al*, 2006; Richards *et al*, 2008), and the BNST receives dense orexinergic innervation (Baldo *et al*, 2003). To test the role of orexin signaling in the effects of yohimbine, we assessed the ability of OxR antagonists to block its actions. When applied alone, the OX₁R antagonist, SB-334867 (5 μ M), had no significant effect on excitatory transmission, even with extensive pretreatment ($91.6 \pm 3.8\%$ of baseline in 86–90 min, $t_6 = 1.03$, $p = \text{n.s.}$, $n = 7$ slices from four mice;

Figure 2a). However, pretreatment with 5 μ M SB-334867 prevented yohimbine-induced depression of excitatory transmission ($101.6 \pm 2.6\%$ of baseline in 86–90 min, $t_5 = 0.4$, $p = \text{n.s.}$, $n = 6$ from four mice, Figure 2b). Similarly, a 30 min application of a novel dual OX₁R and OX₂R antagonist, MTBDQ (1 μ M), also had no effect on excitatory transmission ($98.8 \pm 2.6\%$ % of baseline in 86–90 min, $t_5 = 1.2$, $p = \text{n.s.}$, $n = 6$ slices from three mice, Figure 2d). Similar to what was observed with the OX₁R, pretreatment with 1 μ M MTBDQ prevented yohimbine-induced depression of excitatory transmission ($101.1 \pm 28.3\%$ of baseline in 86–90 min, $t_6 = 0.1$, $p = \text{n.s.}$, $n = 7$ slices from five mice, Figure 2e). These results are summarized as peak drug effects at 86–90 min ($F_{4,26} = 9.9$; $*p < 0.05$ for the yohimbine group compared with all other groups; Figure 2c).

OX₁R-Dependent orexin A-Induced Depression of AMPA EPSCs in the dlBNST

Our findings suggest that an OxR agonist may mimic the effects of yohimbine on excitatory transmission in the dlBNST. Two recent studies reported that in the hippocampus and ventrolateral periaqueductal gray (vlPAG), orexin A elicited a depression of excitatory transmission in young animals (Ho *et al*, 2011; Selbach *et al*, 2010). We thus investigated the effects of exogenous orexin A on excitatory transmission in the dlBNST. Consistent with our hypothesis, in the majority of cells recorded (13 of 16 cells recorded from 10 mice), a 20 min application of 100 nM orexin A resulted in a slowly developing and significant reduction of α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) EPSC amplitude ($41.9 \pm 7.0\%$ decrease from baseline; $t_{12} = 6.3$, $*p < 0.01$, $n = 13$, Figure 3a) and EPSC area ($35.2 \pm 6.2\%$ decrease from baseline: $t_{12} = 6.6$, $*p < 0.05$, Figure 3a inset), with no significant changes to EPSC kinetics (rise: $t_{12} = 0.4$, $p = \text{n.s.}$; decay: $t_{12} = 0.2$, $p = \text{n.s.}$, Figure 3a inset). In the remaining cells (3 of 16 cells recorded), 20 min application of 100 nM orexin A had no significant effect on EPSC amplitude, area, or kinetics (data not shown). PPR and CV analysis was undertaken to investigate changes in presynaptic release probability. Interestingly, PPR ($t_{12} = 3.2$, $*p < 0.05$, Figure 3b) and CV ($t_{12} = 3.4$, $*p < 0.05$, Figure 3c) were increased compared with baseline, consistent with an orexin A-mediated decrease in presynaptic glutamate release probability.

As previous studies suggest the BNST has a moderate to high density of OX₁R and OX₂R mRNA and protein expression (Hervieu *et al*, 2001; Marcus *et al*, 2001), we next investigated whether the orexin A depression of excitatory transmission was OX₁R—or OX₂R-dependent. We found that pretreatment with the OX₁R antagonist, SB-334867 (2 μ M) attenuated the orexin A mediated depression with no significant changes in AMPA EPSC amplitude ($6.6 \pm 9.4\%$ decrease from baseline, $t_4 = 0.2$; $p = \text{n.s.}$, $n = 5$ slices from five mice, Figure 3d). Consistent with these findings, no changes were observed in PPR ($t_4 = 0.1$; $p = \text{n.s.}$, Figure 3e) and CV ($t_4 = 0.1$; $p = \text{n.s.}$, Figure 3f). In contrast, pretreatment with the OX₂R antagonist, JNJ-10397047 (1 μ M) did not prevent a significant reduction in EPSC amplitude by orexin A ($47.8 \pm 4.9\%$ decrease from baseline, $t_4 = 6.7$, $*p < 0.05$, $n = 5$ slices from four mice, Figure 3g). Moreover, an increase in both PPR ($t_4 = 7.4$, $*p < 0.05$, Figure 3h) and CV ($t_4 = 2.9$,




Figure 2 Orexin receptor (OxR) antagonists block yohimbine-induced depression of excitatory transmission in the dorsal anterolateral bed nucleus of the stria terminalis (dBNST). Extracellular field potential recordings of excitatory transmission in the dBNST. (a) 5 μ M SB-334867; seven slices recorded from four mice. (b) 30 μ M yohimbine in the presence of 5 μ M SB-334867; six slices recorded from four mice. (c) Summary of 86–90 min for yohimbine, 2-[4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl]quinazoline (MTBDQ), MTBDQ + yohimbine, SB-334867, SB-334867 + yohimbine. (d) 1 μ M MTBDQ; six slices recorded from three mice. (e) 30 μ M yohimbine in the presence of 1 μ M MTBDQ; seven slices recorded from five mice. Data are represented as mean \pm SEM, * p > 0.05, n = 6–7 slices per group.

* p < 0.05, Figure 3i) were observed, indicating that application of orexin A in the presence of an OX₂R antagonist did not effect presynaptic release probability. These results strongly suggest that orexin A acts at the OX₁R to depress excitatory transmission in dBNST.

Yohimbine Does Not Directly Activate OX₁R Signaling

Our results demonstrate both an OX₁R and novel dual OX₁R/OX₂R antagonist attenuate yohimbine-induced depression of excitatory transmission (Figure 2), and these depressant effects of yohimbine on excitatory transmission are mimicked by orexin A in an OX₁R-dependent manner (Figure 3), indicating that yohimbine depresses excitatory transmission in dBNST by recruiting OxR signaling. This could be accomplished either via direct action of yohimbine on Ox1R, or via regulation of orexin release to activate the receptor. To address the former issue, we investigated the ability of yohimbine to act as a direct ligand and activate the OX₁R utilizing a stable OX₁R cell line and calcium mobilization assay. Increasing concentrations of orexin A, yohimbine, and ATP were applied to HEK-EM4 cells stably expressing the OX₁R and calcium mobilization was measured. The EC₅₀ for orexin A was \sim 72 \pm 6 nM, the EC₅₀ for yohimbine > 1 mM, and the EC₅₀ for ATP was 709 \pm 40 nM in HEK-EM4 cells expressing the OX₁R (Figure 4a). In the HEK-EM4 OX₁R expressing cells the OX₁R antagonist SB-334867 fully inhibited the effects of an EC₈₀ concentration of orexin A (IC₅₀ \sim 109 \pm 3 nM), whereas it had no effect on the signal produced by 1 mM yohimbine

(IC₅₀ > 1 mM; Figure 4b). To determine whether the mM yohimbine concentrations required to observe a calcium mobilization response were related to OX₁R expression, carbachol, yohimbine, and ATP were applied to HEK 293 cells co-expressing mGluR₂ and GIRKs. The EC₅₀ for carbachol was > 30 μ M, EC₅₀ for yohimbine > 1 mM, and the EC₅₀ for ATP was 420 \pm 83 nM (Figure 4c). All experiments were performed in triplicate. These results suggest that yohimbine does not directly recruit OX₁R signaling and more likely acts by indirectly promoting orexin release to influence orexin receptor signaling.

Yohimbine-Induced Depression of Excitatory Transmission in the dBNST is Absent in Prepro-orexin Knockout Mice

If yohimbine acts on dBNST excitatory transmission via promoting the release of orexin, it would be predicted that this effect would be absent in dBNST slices prepared from prepro-orexin knockout (Ox-KO) mice. Thus, we assessed the ability of yohimbine to depress excitatory transmission in the dBNST in Ox-KO mice (Willie *et al*, 2003). Yohimbine (30 μ M, 30 min) had no significant effect on excitatory transmission in the dBNST (94.9 \pm 7.2% of baseline in 86–90 min, t_4 = 0.5, p = n.s., n = 5 slices from three mice, Figure 5) in slices from Ox-KO mice; consistent with the idea that yohimbine acts via promoting orexin release in the dBNST to depress glutamatergic transmission.




Figure 3 OX₁R-dependent orexin A-induced depression of α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) EPSCs in the dBNST. Whole-cell patchclamp recordings of AMPA EPSCs in the dBNST. (a) Time course showing the effect of 100 nM orexin A on the peak amplitude of AMPA EPSCs in 13 out of 16 cells recorded from 10 mice; inset: representative trace from whole-cell recording (baseline: black line; post-orexin A: blue line); boxed inset: Summary of cell parameters monitored throughout recordings: amplitude, access resistance (Ra), area, rise time, and decay time of EPSCs. * indicated significant difference from baseline. (b) PPR of pre-orexin A and post-orexin A application. (c) % coefficient of variation (CV) in pre-orexin A and post-orexin A events. (d) Time course showing the effect of 100 nM orexin A in the presence of 2 μ M of the OX₁R (orexin receptor 1) antagonist, SB-334867, on the peak amplitude of AMPA EPSCs in 5 out of 5 cells recorded from five mice. Boxed Inset: Summary of cell parameters monitored throughout recordings: amplitude, access resistance (Ra), area, rise time, and decay time of EPSCs * indicated significant difference from baseline. (e) In the presence of SB-334867, PPR of pre-orexin A and post-orexin A application. (f) In the presence of SB-334867, % CV of pre-orexin A and post-orexin A events. (g) Time course showing the effect of 100 nM orexin A in the presence of 1 μ M of the OX₂R antagonist, JNJ-10397047, on the peak amplitude of AMPA EPSCs in 5 out of 5 cells recorded from four mice. Boxed Inset: Summary of cell parameters monitored throughout recordings: amplitude, access resistance (Ra), area, rise time, and decay time of EPSCs * indicated significant difference from baseline. (h) In the presence of JNJ-10397047, PPR of pre-orexin A and post-orexin A application. (i) In the presence of JNJ-10397047, % CV of pre-orexin A and post-orexin A events. The color reproduction of the figure is available at the *Neuropsychopharmacology* journal online.

α_1 -AR-Induced Depression of Excitatory Transmission in the dBNST is Not Blocked by an OX₁R Antagonist

As shown above, orexin A, acting at the OX₁R, depresses excitatory transmission in the dBNST. Similarly, previous work in our lab has demonstrated that several other

Gq-linked receptors (eg, α_1 -AR, mGluR1, mGluR5) cause a depression of excitatory transmission in the dBNST (Gosnell *et al*, 2011; Grueter *et al*, 2006; McElligott *et al*, 2010; McElligott and Winder, 2008, 2009). Although the α_1 -AR antagonist prazosin did not block yohimbine-induced depression of excitatory transmission (see above), to further




Figure 4 Yohimbine does not directly activate OX₁R signaling. Concentration–response curves (CRCs) of (a) orexin A, yohimbine, and ATP in HEK-EM4 cells expressing orexin 1 receptor (OX₁R-Cs). (b) Effects of 1 mM yohimbine or EC80 orexin A in SB-334867 pre-treated OX₁R-Cs. (c) Carbachol, yohimbine, and ATP in HEK 293 cell co-expressing rat mGluR₂ and G-protein-coupled inwardly rectifying potassium (GIRK) channels (mGluR₂ Cell Line). All data are expressed as the mean of a minimum of three independent experiments performed in triplicate. Data are represented as mean ± SEM.




Figure 5 Yohimbine-induced depression of excitatory transmission in the dlbnst is absent in prepro-orexin (ox) knockout mice. Extracellular field potential recordings of excitatory transmission in the dlBNST of prepro-orexin knockout (Ox-KO) mice. 30 μM yohimbine. Data are represented as mean ± SEM, $p = n.s.$, $n = 5$ slices from three mice.

address possible activation of common downstream effectors, we investigated if an OX₁R antagonist could block methoxamine (a Gq-linked α_1 -AR)-induced depression in the dlBNST. A 30 min application of methoxamine (100 μM) elicited a significant depression in excitatory transmission ($66.1 \pm 3.5\%$ of baseline in 86–90 min, $t_5 = 6.2$, $*p < 0.05$, $n = 6$ slices from four mice, Figure 6a). A 30 min application of 100 μM methoxamine in the presence of 5 μM SB-334867 still elicited a significant depression of excitatory transmission ($71.7 \pm 4.3\%$ of baseline in 86–90 min, $t_6 = 7.5$, $*p < 0.05$, $n = 7$ slices from four mice, Figure 6b) that was not significantly different from the depression elicited by 100 μM methoxamine alone ($F_{2,17} = 10.9$, $*p < 0.05$ for

methoxamine compared to SB-334867, $*p < 0.05$ for SB-334867 + methoxamine compared with SB-334867, $p = n.s.$ for methoxamine compared with methoxamine + SB-334867; Figure 6c). Taken together, these results demonstrate that the α_1 -AR mediated depression of excitatory transmission is independent from the yohimbine-inducible and OX₁R-dependent depression of excitatory transmission observed in the dlBNST.

OX₁R Antagonist, SB-334867, Blocks Yohimbine-induced Impairment of Extinction of Cocaine-CPP in α_{2A} -AR Wild-Type and KnockOut Mice

Recent studies have demonstrated that an OX₁R antagonist, SB-334867, can attenuate yohimbine-induced reinstatement of drug-seeking behavior (Richards *et al*, 2008; Zhou *et al*, 2011). However, the role of OX₁R in the extinction of stress-induced increases in cocaine-seeking behavior is unknown. Although our understanding of the neural mechanisms and substrates critical to reinstatement of drug-seeking behavior have increased substantially in recent years, the role of a potentially therapeutically viable method to help achieve and maintain abstinence, extinction training, has lagged considerably (Millan *et al*, 2011; Myers and Carlezon, 2010). To determine if systemic administration of an OX₁R antagonist (SB-334867) can attenuate yohimbine-induced impairment of extinction of cocaine-CPP, α_{2A} -AR wild-type (α_{2A} -AR-WT) and knockout (α_{2A} -AR-KO) mice were tested using a previously employed cocaine-CPP and extinction paradigm (Davis *et al*, 2008). α_{2A} -AR-WT and KO littermate mice display cocaine-CPP when tested during a 15-min post-test session (post-test preference expressed compared with pre-test




Figure 6 α_1 -AR-induced Depression of Excitatory Transmission in the dBNST is Not Blocked by an OX₁R Antagonist. Extracellular field potential recordings of excitatory transmission in the dBNST (a) 100 μ M methoxamine; $n=6$ slices from four mice; (b) 100 μ M methoxamine in the presence of 5 μ M SB-334867; $n=7$ slices from four mice; (c) summary of 86–90 min for methoxamine and SB-334867 + methoxamine. Data are represented as mean \pm SEM, * $p < 0.05$, $n=5-7$ slices per group.

values for α_{2A} -AR-WT: $t=4.7$, * $p < 0.01$, $n=51$, Figure 7a; post-test preference expressed compared with pre-test values for α_{2A} -AR-KO: $t=8.9$, * $p < 0.01$, $n=32$, Figure 7a). The magnitude of preference expressed did not differ between α_{2A} -AR-WT and α_{2A} -AR-KO mice. ($t_{81}=1.1$, $p=n.s.$, Figure 7a). In the WT mice cohort, mice were assigned to one of four groups and treated with yohimbine 30 min before the extinction session (5 mg/kg; WT-YOH), SB-334867 1 h before the extinction session (15 mg/kg; WT-SB), saline 1 h and 30 min before the extinction sessions (WT-Sal) or mice pre-treated with SB-334867 1 h before and yohimbine 30 min before the extinction sessions (WT-SB-YOH). Doses used for yohimbine and SB-334867 were determined based on previous studies (Davis et al, 2008; Richards et al, 2008). In WT mice, two-way ANOVA RM revealed a significant effect (Figure 7b) of time ($F_{5,260}=19.89$), treatment ($F_{3,260}=2.92$),




Figure 7 OX₁R antagonist, SB-334867, blocks yohimbine-induced impairment of extinction of cocaine-CPP in α_{2A} -AR wild-type and knockout mice. Magnitude of cocaine place preference assessed in a drug-free state during the pre and post preference test. All mice were conditioned with a 20 mg/kg dose of cocaine to the cocaine paired side (see Patients and Methods for additional details). (a) α_{2A} -AR wild-type and knockout mice display cocaine-CPP. (b) Mice treated with yohimbine (5 mg/kg; WT-Yoh) display impaired extinction of cocaine-CPP on extinction (Ext) days 1 and 2 but not on extinction days 3, 4, and 5. SB-334867 (15 mg/kg; WT-SB) and SB-334867 and yohimbine (5 and 15 mg/kg respectively; WT-SB-Yoh) mice display levels similar to saline (WT-Sal) mice on all extinction days. (c) Mice treated with yohimbine (5 mg/kg; KO-Yoh) display impaired extinction of cocaine-CPP on extinction (Ext) days 1, 2, and 3 but not on extinction days 4 and 5. SB-334867 (15 mg/kg; KO-SB) and SB-334867 and yohimbine (5 mg/kg and 15 mg/kg respectively; KO-SB-Yoh) mice display levels similar to saline (KO-Sal) mice on all extinction days. Data are represented as mean \pm SEM. * $p < 0.05$ when YOH group is significantly different from SB-YOH, # $p < 0.05$ when YOH group is significantly different from SAL, & $p < 0.05$ when YOH group is significantly different from SB group.

and time x treatment interaction ($F_{15,260}=1.76$). Post-hoc analysis revealed a significant effect of WT-YOH on extinction day one compared to WT-SB-YOH ($t=3.867$;

* $p < 0.05$), WT-SAL ($t = 3.174$; # $p < 0.05$), and WT-SB ($t = 2.689$; & $p < 0.05$) and a significant effect of WT-YOH on extinction day 2 compared to WT-SB-YOH ($t = 2.859$; * $p < 0.05$). No differences were found on distance traveled in any α_{2A} -AR WT group tested during extinction days 1–5 (data not shown). These results demonstrate that systemic administration of an antagonist of the OX₁R prevents yohimbine-mediated impairment of extinction of cocaine-CPP, yet the OX₁R alone had no effect on the rate of extinction.

Given the putative role of the α_2 -AR in mediating the anxiogenic and drug-seeking related effects of yohimbine, we next investigated if an antagonist of the OX₁R could still alter the yohimbine-mediated increase in time spent in the chamber previously associated with cocaine in mice lacking the α_{2A} -AR. In the α_{2A} -AR-KO cohort, mice were assigned to 1 of 4 groups and treated with yohimbine 30 min before the extinction session (5 mg/kg; KO-YOH), SB-334867 1 h before the extinction session (15 mg/kg; KO-SB), saline 1 h and 30 min prior (KO-Sal) or mice pre-treated with SB-334867 1 h prior and yohimbine 30 min before the extinction sessions (KO-SB-YOH). In KO mice, two-way ANOVA RM revealed a significant effect (Figure 7c) of time ($F_{5,129} = 42.50$), treatment ($F_{3,129} = 5.61$), but not time x treatment interaction. *Post-hoc* analysis revealed a significant effect of KO-YOH on extinction day one compared to KO-SB-YOH ($t = 4.291$; * $p < 0.05$), and KO-SB ($t = 3.1$; & $p < 0.05$); KO-YOH on extinction day two compared to KO-SB-YOH ($t = 3.0351$; * $p < 0.05$); KO-YOH on extinction day three compared to KO-SB-YOH ($t = 3.782$; * $p < 0.05$), KO-SAL ($t = 3.346$; # $p < 0.05$), and KO-SB ($t = 3.015$; & $p < 0.05$). No differences were found on distance traveled in any α_{2A} -AR wild-type group tested during extinction days 1–5 (data not shown). Taken together, these results demonstrate that an OX₁R antagonist can prevent yohimbine-induced impairment of extinction, both in wild-type and α_{2A} -AR-KO mice.

DISCUSSION

We found that yohimbine depresses excitatory transmission in the dlBNST via OX₁R-dependent signaling, and this depressant effect was blocked both by an OX₁R and a novel dual OX₁R/OX₂R antagonist, but not antagonists of α_1 -AR and CRFR₁, nor mimicked by a norepinephrine transporter blocker. Moreover, the depressant effects of yohimbine on excitatory transmission in the BNST were mimicked by orexin A acting at the OX₁R but not OX₂R, demonstrating a novel action of orexin in the BNST. Additionally, we found that yohimbine did not activate OX₁Rs in a stable cell line, and yohimbine depression of excitatory transmission was absent in slices prepared from OX-KO mice. Yohimbine likely depresses excitatory transmission in BNST through orexin-dependent activation of OX₁R to decrease glutamate release probability, as whole-cell recordings demonstrated an OX₁R-dependent increase in both PPR and CV. In parallel, we find that the ability of yohimbine to impair extinction of cocaine-CPP in α_{2A} -AR-WT and α_{2A} -AR-KO mice is blocked by systemic administration of the OX₁R antagonist SB-334867.

Yohimbine Recruits OX₁R Signaling to Depress Excitatory Transmission in the BNST

Utilizing extracellular recordings, we replicated previous whole-cell recordings demonstrating yohimbine depresses excitatory transmission in dlBNST (Davis *et al*, 2008). Yohimbine-induced depression is intact in α_{2A} -AR KO mice, suggesting an off-target action of the drug. While yohimbine could be acting through antagonism of α_{2B} - and/or α_{2C} -AR subtypes (Altman *et al*, 1999), the α_2 -AR agonist UK 14304 depresses excitatory transmission but is attenuated rather than mimicked by the α_2 -AR antagonist, atipamezole (Davis *et al*, 2008; Egli *et al*, 2005). Furthermore, it is unlikely that the effects observed here involve autoreceptor functions of α_2 -AR activity, because the norepinephrine transport blocker reboxetine did not mimic yohimbine, and the α_1 -AR antagonist prazosin did not block it. Yohimbine is known to have relatively moderate- to high-affinity for a number of GPCRs other than α_2 -ARs, including serotonin (5-HT)(1A), 5-HT(1B) receptors among others (Millan *et al*, 2000). Indeed, the actions of yohimbine on reinstatement of cocaine- and alcohol-seeking has been shown to involve 5HT and β -adrenergic receptors (β -ARs) (Dzung Le *et al*, 2009; Fletcher *et al*, 2008; Sakurai *et al*, 1998). However, the actions of β -AR and 5HT receptor agonists on excitatory transmission in BNST differ from the known actions of yohimbine at these receptors (Guo and Rainnie, 2010; Hammack *et al*, 2009; Nobis *et al*, 2011). For example, previous work from our group demonstrated a β -AR agonist enhances excitatory transmission in BNST (Nobis *et al*, 2011). Moreover, a 5HT-1A and 5HT-2C agonist has no effect and a 5HT-1B agonist depresses excitatory transmission in the BNST (Guo *et al*, 2009; Guo and Rainnie, 2010), yet yohimbine is known to act as an antagonist at 5HT-1B and has no significant affinity for β -ARs (Millan *et al*, 2000), suggesting a different target may better explain the effects of yohimbine in BNST.

Based on previous studies that had separately shown that the BNST is an important site for yohimbine actions in stress and anxiety-related behavior (Buffalari and See, 2010; Johnson *et al*, 2010), we hypothesized that yohimbine interacts with orexin signaling to alter glutamatergic transmission. Indeed, yohimbine-induced depression was sensitive to OX₁R and a dual OX₁R/OX₂R antagonism, and mimicked by exogenous orexin A application. Finally, an absence of yohimbine-induced depression on excitatory transmission in the OX-KO confirms the necessity of the orexin system in mediating the effects of yohimbine on excitatory transmission in the BNST.

Orexin A Depresses Excitatory Transmission in the BNST in an OX₁R-Dependent Manner

Our results indicate a novel role for orexin A in depressing excitatory transmission in the dlBNST of adult mice, while studies in other brain regions have predominantly demonstrated excitatory roles (Bisetti *et al*, 2006; Burlet *et al*, 2002; Follwell and Ferguson, 2002; Hagan *et al*, 1999; Sakurai *et al*, 1998; Shin *et al*, 2009; Shirasaka *et al*, 2001; Soffin *et al*, 2002; Sutcliffe and de Lecea, 2000; Yang *et al*, 2003). This dichotomy of actions of GPCRs on neuronal function is not unusual. The Gq-linked mGluR5 and α_1 -AR both induce

depression of excitatory transmission yet enhance NMDA receptor function (Grueter and Winder, 2005; Kirkwood *et al*, 1999; McElligott and Winder, 2009; McElligott *et al*, 2010). Moreover, two recent studies reported that in the hippocampus and ventrolateral periaqueductal gray (vlPAG), orexin A elicited a depression of excitatory transmission in young animals (Ho *et al*, 2011; Selbach *et al*, 2010).

Yohimbine Acts Indirectly at the OX₁R

Our results with the OX₁R cell line indicate that yohimbine is not a direct ligand for OX₁R. Indeed, a concentration of 1 mM yohimbine and above was necessary to observe any calcium mobilization. This effect was not blocked by the OX₁R antagonist, SB-334867, and was also evident in a cell line expressing mGluR2 rather than OX₁R, indicating that it was independent of OX₁R signaling. It should be noted, however, that we cannot exclude the possibility that OX₁R *in vivo* responds differently to yohimbine than in cell lines. For example, Gq-linked elevations in postsynaptic Ca²⁺ levels have been shown to lead to endocannabinoid-mediated retrograde signaling (Wettschureck *et al*, 2006). Within the BNST, activation of the cannabinoid 1 receptor (CB1) depresses excitatory transmission (Grueter *et al*, 2006; Puente *et al*, 2010). As our PPR and CV analysis indicate a decrease in presynaptic glutamate release probability, future studies will investigate the potential role for CB1-mediated retrograde signaling on the OX₁R-dependent yohimbine-induced depression of excitatory transmission. Our results demonstrate that deletion of orexin via the use of OX-KO mice blocked the yohimbine-induced depression of excitatory transmission and it seems most likely that in the BNST yohimbine acts indirectly to promote orexin A release to influence synaptic function and impact behavior.

OX₁R Mediates Yohimbine-impaired Cocaine Extinction

As we found that the depressant effects of yohimbine in the BNST require orexin signaling, we wondered whether behavioral actions of yohimbine would also require the actions of this neuropeptide. To date, studies on the role of the orexin system on cocaine relapse behavior have focused primarily on reinstatement. In the present study, we sought to investigate the potential involvement of orexin in mediating the effects of stress on cocaine extinction.

We found that systemic OX₁R antagonism blunted yohimbine-impaired extinction of cocaine-CPP in α_{2A} -AR WT and KO mice. Consistent with our findings that the OX₁R is involved in extinction of cocaine reward are reports that the OX₁R mediates yohimbine-induced reinstatement of alcohol- and cocaine-seeking behavior (Buffalari and See, 2010; Zhou *et al*, 2011). Recent studies have also highlighted the interaction of yohimbine with non-OX₁R neuropeptides, such as CRFR₁ (Marinelli *et al*, 2007). However, given that (1) Brown *et al* (2009) demonstrated that a CRFR antagonist failed to block yohimbine-induced reinstatement of cocaine-seeking behavior and (2) we found no effect of the CRF₁ antagonist, NBI-27914, on yohimbine-induced depression of excitatory transmission, it seems unlikely but remains to be examined the behavioral effects of CRFR₁

antagonism on yohimbine-induced impairment of extinction of cocaine-CPP. Moreover, a role for norepinephrine involvement in our reported behavior also seems unlikely, as an OX₁R antagonist was similarly effective at blocking yohimbine-impaired cocaine-CPP extinction in both α_{2A} -AR WT and KO mice. Indeed, previous work demonstrated that the α_2 -AR antagonist, atipamezole, also failed to impair extinction of cocaine-CPP (Davis *et al* 2008). On alcohol self-administration and reinstatement, the effects of yohimbine are not mimicked by a highly selective α_2 -AR antagonist, RS-79948, nor were the effects of yohimbine on self-administration blocked by the α_2 -AR agonist clonidine (Dzung Le *et al*, 2009). Similarly, neither clonidine nor prazosin block yohimbine-induced reinstatement of cocaine-seeking behavior (Brown *et al*, 2009).

Conclusions

Taken together, these data demonstrate an important new mechanism for orexin action, and show that significant behavioral actions of yohimbine may be independent of adrenergic signaling and instead require OX₁R in the BNST. Moreover, our data does not preclude the additional possibility that orexin acts upstream of yohimbine to facilitate yohimbine-induced impairment of excitatory transmission. However, our data do strongly suggest little role, if any, for the norepinephrine system in the depressant effects of yohimbine on glutamatergic transmission. Given the pivotal role stress has during withdrawal in enhancing susceptibility to cocaine-seeking behavior, our data highlight an important role for orexin in mediating stress-induced impairment of the extinction of cocaine-seeking behavior. Moreover, our data implicating a role for OX₁R in stress- and reward-related cocaine extinction behavior is paralleled by changes in neuronal function in the BNST and reveals a novel action of orexin in depressing excitatory transmission, likely through a presynaptic decrease in the release probability of glutamate. Our data indicate that continued investigation of the actions of orexin on synaptic plasticity in the BNST, a region critical to the integration of stress and cocaine reward information, is clearly warranted. Moreover, as our study establishes yohimbine lacks direct agonist activity at the OX₁R, future studies should address the precise target(s) and underlying mechanism by which yohimbine affects orexin release and/or signaling in the dlBNST.

ACKNOWLEDGEMENTS

The behavioral data presented in this manuscript were generated at the Vanderbilt Murine Neurobehavioral Laboratory: <http://kc.vanderbilt.edu/mnlcore/>. We would like to thank Dr John Allison and Elana Epstein for their generous assistance and expertise. This work was supported by National Institutes of Health Grants NS07491 and MH065215-08 (KLC) and AA019455 AND DA019112 (DGW).

DISCLOSURE

The authors declare no conflict of interest.

REFERENCES

- Abercrombie ED, Keller Jr RW, Zigmond MJ (1988). Characterization of hippocampal norepinephrine release as measured by microdialysis perfusion: pharmacological and behavioral studies. *Neuroscience* **27**: 897–904.
- Aghajanian GK, VanderMaelen CP (1982). alpha 2-adrenoceptor-mediated hyperpolarization of locus coeruleus neurons: intracellular studies *in vivo*. *Science* **215**: 1394–1396.
- Altman JD, Trendelenburg AU, MacMillan L, Bernstein D, Limbird L, Starke K *et al* (1999). Abnormal regulation of the sympathetic nervous system in alpha2A-adrenergic receptor knockout mice. *Mol Pharmacol* **56**: 154–161.
- Baldo BA, Daniel RA, Berridge CW, Kelley AE (2003). Overlapping distributions of orexin/hypocretin- and dopamine-beta-hydroxylase immunoreactive fibers in rat brain regions mediating arousal, motivation, and stress. *J Comp Neurol* **464**: 220–237.
- Banihashemi L, Rinaman L (2006). Noradrenergic inputs to the bed nucleus of the stria terminalis and paraventricular nucleus of the hypothalamus underlie hypothalamic-pituitary-adrenal axis but not hypophagic or conditioned avoidance responses to systemic yohimbine. *J Neurosci (Official J Soc Neurosci)* **26**: 11442–11453.
- Bisetti A, Cvetkovic V, Serafin M, Bayer L, Machard D, Jones BE *et al* (2006). Excitatory action of hypocretin/orexin on neurons of the central medial amygdala. *Neuroscience* **142**: 999–1004.
- Boutrel B, Kenny PJ, Specio SE, Martin-Fardon R, Markou A, Koob GF *et al* (2005). Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. *Proc Natl Acad Sci USA* **102**: 19168–19173.
- Brown ZJ, Tribe E, D'Souza N A, Erb S (2009). Interaction between noradrenaline and corticotrophin-releasing factor in the reinstatement of cocaine seeking in the rat. *Psychopharmacology* **203**: 121–130.
- Buffalari DM, See RE (2010). Inactivation of the bed nucleus of the stria terminalis in an animal model of relapse: effects on conditioned cue-induced reinstatement and its enhancement by yohimbine. *Psychopharmacology (Berl)* **213**: 19–27.
- Burlet S, Tyler CJ, Leonard CS (2002). Direct and indirect excitation of laterodorsal tegmental neurons by Hypocretin/Orexin peptides: implications for wakefulness and narcolepsy. *J Neurosci* **22**: 2862–2872.
- Cain CK, Blouin AM, Barad M (2004). Adrenergic transmission facilitates extinction of conditional fear in mice. *Learn Mem* **11**: 179–187.
- Champagne D, Beaulieu J, Drolet G (1998). CRFergic innervation of the paraventricular nucleus of the rat hypothalamus: a tract-tracing study. *J Neuroendocrinol* **10**: 119–131.
- Davis AR, Shields AD, Brigman JL, Norcross M, McElligott ZA, Holmes A *et al* (2008). Yohimbine impairs extinction of cocaine-conditioned place preference in an alpha2-adrenergic receptor independent process. *Learn Mem* **15**: 667–676.
- Dayas CV, McGranahan TM, Martin-Fardon R, Weiss F (2008). Stimuli linked to ethanol availability activate hypothalamic CART and orexin neurons in a reinstatement model of relapse. *Biol Psychiatry* **63**: 152–157.
- de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE *et al* (1998). The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. *Proc Natl Acad Sci USA* **95**: 322–327.
- Dzung Le A, Funk D, Harding S, Juzysch W, Fletcher PJ (2009). The role of noradrenaline and 5-hydroxytryptamine in yohimbine-induced increases in alcohol-seeking in rats. *Psychopharmacology* **204**: 477–488.
- Egli RE, Kash TL, Choo K, Savchenko V, Matthews RT, Blakely RD *et al* (2005). Norepinephrine modulates glutamatergic transmission in the bed nucleus of the stria terminalis. *Neuropsychopharmacology* **30**: 657–668.
- Erb S, Salmaso N, Rodaros D, Stewart J (2001). A role for the CRF-containing pathway from central nucleus of the amygdala to bed nucleus of the stria terminalis in the stress-induced reinstatement of cocaine seeking in rats. *Psychopharmacology* **158**: 360–365.
- Espana RA, Oleson EB, Locke JL, Brookshire BR, Roberts DC, Jones SR (2010). The hypocretin-orexin system regulates cocaine self-administration via actions on the mesolimbic dopamine system. *European J Neurosci* **31**: 336–348.
- Fletcher PJ, Rizos Z, Sinyard J, Tampakeras M, Higgins GA (2008). The 5-HT_{2C} receptor agonist Ro60-0175 reduces cocaine self-administration and reinstatement induced by the stressor yohimbine, and contextual cues. *Neuropsychopharmacology (Official Publ Am College Neuropsychopharmacol)* **33**: 1402–1412.
- Follwell MJ, Ferguson AV (2002). Cellular mechanisms of orexin actions on paraventricular nucleus neurones in rat hypothalamus. *J Physiol* **545**(Pt 3): 855–867.
- Franklin KBJ, Paxinos G (1997). *The Mouse Brain in Stereotaxic Coordinates*. Academic Press, Inc.: San Diego.
- Gosnell HB, Silberman Y, Grueter BA, Duvoisin RM, Raber J, Winder DG (2011). mGluR8 modulates excitatory transmission in the bed nucleus of the stria terminalis in a stress-dependent manner. *Neuropsychopharmacology (Official Publ Am College Neuropsychopharmacol)* **36**: 1599–1607.
- Grueter BA, Gosnell HB, Olsen CM, Schramm-Sapota NL, Nekrasova T, Landreth GE *et al* (2006). Extracellular-signal regulated kinase 1-dependent metabotropic glutamate receptor 5-induced long-term depression in the bed nucleus of the stria terminalis is disrupted by cocaine administration. *J Neurosci (Official J Soc Neurosci)* **26**: 3210–3219.
- Grueter BA, Winder DG (2005). Group II and III metabotropic glutamate receptors suppress excitatory synaptic transmission in the dorsolateral bed nucleus of the stria terminalis. *Neuropsychopharmacology* **30**: 1302–1311.
- Guo JD, Hammack SE, Hazra R, Levita L, Rainnie DG (2009). Bi-directional modulation of bed nucleus of stria terminalis neurons by 5-HT: molecular expression and functional properties of excitatory 5-HT receptor subtypes. *Neuroscience* **164**: 1776–1793.
- Guo JD, Rainnie DG (2010). Presynaptic 5-HT(1B) receptor-mediated serotonergic inhibition of glutamate transmission in the bed nucleus of the stria terminalis. *Neuroscience* **165**: 1390–1401.
- Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S *et al* (1999). Orexin A activates locus coeruleus cell firing and increases arousal in the rat. *Proc Natl Acad Sci USA* **96**: 10911–10916.
- Hammack SE, Guo JD, Hazra R, Dabrowska J, Myers KM, Rainnie DG (2009). The response of neurons in the bed nucleus of the stria terminalis to serotonin: implications for anxiety. *Prog Neuropsychopharmacol Biol Psychiatry* **33**: 1309–1320.
- Harris GC, Wimmer M, Aston-Jones G (2005). A role for lateral hypothalamic orexin neurons in reward seeking. *Nature* **437**: 556–559.
- Hefner K, Whittle N, Juhasz J, Norcross M, Karlsson RM, Saksida LM *et al* (2008). Impaired fear extinction learning and cortico-amygdala circuit abnormalities in a common genetic mouse strain. *J Neurosci (Official J Soc Neurosci)* **28**: 8074–8085.
- Hervieu GJ, Cluderay JE, Harrison DC, Roberts JC, Leslie RA (2001). Gene expression and protein distribution of the orexin-1 receptor in the rat brain and spinal cord. *Neuroscience* **103**: 777–797.
- Ho YC, Lee HJ, Tung LW, Liao YY, Fu SY, Teng SF *et al* (2011). Activation of orexin 1 receptors in the periaqueductal gray of male rats leads to antinociception via retrograde endocannabinoid (2-arachidonoylglycerol)-induced disinhibition. *J Neurosci (Official J Soc Neurosci)* **31**: 14600–14610.

- Jin X, Semenova S, Yang L, Ardecky R, Sheffler DJ, Dahl R *et al* (2010). The mGluR2 positive allosteric modulator BINA decreases cocaine self-administration and cue-induced cocaine-seeking and counteracts cocaine-induced enhancement of brain reward function in rats. *Neuropsychopharmacology* 35: 2021–2036.
- Johnson PL, Truitt W, Fitz SD, Minick PE, Dietrich A, Sanghani S *et al* (2010). A key role for orexin in panic anxiety. *Nat Med* 16: 111–115.
- Kash TL, Winder DG (2006). Neuropeptide Y and corticotropin-releasing factor bi-directionally modulate inhibitory synaptic transmission in the bed nucleus of the stria terminalis. *Neuropharmacology* 51: 1013–1022.
- Kirkwood A, Rozas C, Kirkwood J, Perez F, Bear MF (1999). Modulation of long-term synaptic depression in visual cortex by acetylcholine and norepinephrine. *J Neurosci (Official J Soc Neurosci)* 19: 1599–1609.
- Kupferschmidt DA, Tribe E, Erb S (2009). Effects of repeated yohimbine on the extinction and reinstatement of cocaine seeking. *Pharmacol, Biochem, and Behav* 91: 473–480.
- Lawrence AJ, Cowen MS, Yang HJ, Chen F, Oldfield B (2006). The orexin system regulates alcohol-seeking in rats. *Br J Pharmacol* 148: 752–759.
- Le AD, Funk D, Juzysch W, Coen K, Navarre BM, Cifani C *et al* (2011). Effect of prazosin and guanfacine on stress-induced reinstatement of alcohol and food seeking in rats. *Psychopharmacology* 218: 89–99.
- Leri F, Flores J, Rodaros D, Stewart J (2002). Blockade of stress-induced but not cocaine-induced reinstatement by infusion of noradrenergic antagonists into the bed nucleus of the stria terminalis or the central nucleus of the amygdala. *J Neurosci (Official J Soc Neurosci)* 22: 5713–5718.
- Marcus JN, Aschkenasi CJ, Lee CE, Chemelli RM, Saper CB, Yanagisawa M *et al* (2001). Differential expression of orexin receptors 1 and 2 in the rat brain. *J Comp Neurol* 435: 6–25.
- Marinelli PW, Funk D, Juzysch W, Harding S, Rice KC, Shaham Y *et al* (2007). The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol self-administration and reinstatement of alcohol seeking in rats. *Psychopharmacology (Berl)* 195: 345–355.
- McDougle CJ, Black JE, Malison RT, Zimmermann RC, Kosten TR, Heninger GR *et al* (1994). Noradrenergic dysregulation during discontinuation of cocaine use in addicts. *Arch Gen Psychiatry* 51: 713–719.
- McElligott ZA, Klug JR, Nobis WP, Patel S, Grueter BA, Kash TL *et al* (2010). Distinct forms of Gq-receptor-dependent plasticity of excitatory transmission in the BNST are differentially affected by stress. *Proc Natl Acad Sci USA* 107: 2271–2276.
- McElligott ZA, Winder DG (2008). Alpha1-adrenergic receptor-induced heterosynaptic long-term depression in the bed nucleus of the stria terminalis is disrupted in mouse models of affective disorders. *Neuropsychopharmacology* 33: 2313–2323.
- McElligott ZA, Winder DG (2009). Modulation of glutamatergic synaptic transmission in the bed nucleus of the stria terminalis. *Prog Neuro-Psychopharmacol Biol Psychiatry* 33: 1329–1335.
- Millan EZ, Marchant NJ, McNally GP (2011). Extinction of drug seeking. *Behav Brain Res* 217: 454–462.
- Millan MJ, Newman-Tancredi A, Audinot V, Cussac D, Lejeune F, Nicolas JP *et al* (2000). Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states. *Synapse* 35: 79–95.
- Myers EA, Banihashemi L, Rinaman L (2005). The anxiogenic drug yohimbine activates central viscerosensory circuits in rats. *J Comp Neurol* 492: 426–441.
- Myers KM, Carlezon Jr WA (2010). Extinction of drug- and withdrawal-paired cues in animal models: relevance to the treatment of addiction. *Neurosci Biobehav Rev* 35: 285–302.
- Niswender CM, Johnson KA, Luo Q, Ayala JE, Kim C, Conn PJ *et al* (2008). A novel assay of Gi/o-linked G protein-coupled receptor coupling to potassium channels provides new insights into the pharmacology of the group III metabotropic glutamate receptors. *Mol Pharmacol* 73: 1213–1224.
- Nobis WP, Kash TL, Silberman Y, Winder DG (2011). beta-Adrenergic receptors enhance excitatory transmission in the bed nucleus of the stria terminalis through a corticotrophin-releasing factor receptor-dependent and cocaine-regulated mechanism. *Biol Psychiatry* 69: 1083–1090.
- Porter RA, Chan WN, Coulton S, Johns A, Hadley MS, Widdowson K *et al* (2001). 1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor. *Bioorg Med Chem Lett* 11: 1907–1910.
- Puente N, Elezgarai I, Lafourcade M, Reguero L, Marsicano G, Georges F *et al* (2010). Localization and function of the cannabinoid CB1 receptor in the anterolateral bed nucleus of the stria terminalis. *Plos One* 5: e8869.
- Richards JK, Simms JA, Steensland P, Taha SA, Borgland SL, Bonci A *et al* (2008). Inhibition of orexin-1/hypocretin-1 receptors inhibits yohimbine-induced reinstatement of ethanol and sucrose seeking in Long-Evans rats. *Psychopharmacology (Berl)* 199: 109–117.
- Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H *et al* (1998). Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. *Cell* 92: 573–585.
- Selbach O, Bohla C, Barbara A, Doreulee N, Eriksson KS, Sergeeva OA *et al* (2010). Orexins/hypocretins control bistability of hippocampal long-term synaptic plasticity through co-activation of multiple kinases. *Acta Physiol (Oxf)* 198: 277–285.
- Shaham Y, Erb S, Stewart J (2000). Stress-induced relapse to heroin and cocaine seeking in rats: a review. *Brain Res Brain Res Rev* 33: 13–33.
- Shalev U, Erb S, Shaham Y (2010). Role of CRF and other neuropeptides in stress-induced reinstatement of drug seeking. *Brain Res* 1314: 15–28.
- Shields AD, Wang Q, Winder DG (2009). alpha2A-adrenergic receptors heterosynaptically regulate glutamatergic transmission in the bed nucleus of the stria terminalis. *Neuroscience* 163: 339–351.
- Shin HS, Cho HS, Sung KW, Yoon BJ (2009). Orexin-A increases cell surface expression of AMPA receptors in the striatum. *Biochem Biophys Res Commun* 378: 409–413.
- Shirasaka T, Miyahara S, Kunitake T, Jin QH, Kato K, Takasaki M *et al* (2001). Orexin depolarizes rat hypothalamic paraventricular nucleus neurons. *Am J Physiol Regul Integr Comp Physiol* 281: R1114–R1118.
- Soffin EM, Evans ML, Gill CH, Harries MH, Benham CD, Davies CH (2002). SB-334867-A antagonises orexin mediated excitation in the locus coeruleus. *Neuropharmacology* 42: 127–133.
- Starke K (2001). Presynaptic autoreceptors in the third decade: focus on alpha2-adrenoceptors. *J Neurochem* 78: 685–693.
- Stine SM, Southwick SM, Petrakis IL, Kosten TR, Charney DS, Krystal JH (2002). Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients. *Biol Psychiatry* 51: 642–651.
- Sutcliffe JG, de Lecea L (2000). The hypocretins: excitatory neuromodulatory peptides for multiple homeostatic systems, including sleep and feeding. *J Neurosci Res* 62: 161–168.
- Weitlauf C, Egli RE, Grueter BA, Winder DG (2004). High-frequency stimulation induces ethanol-sensitive long-term potentiation at glutamatergic synapses in the dorsolateral bed nucleus of the stria terminalis. *J Neurosci* 24: 5741–5747.
- Wettschureck N, van der Stelt M, Tsubokawa H, Krestel H, Moers A, Petrosino S *et al* (2006). Forebrain-specific inactivation of Gq/G11 family G proteins results in age-dependent epilepsy

- and impaired endocannabinoid formation. *Mol Cell Biol* **26**: 5888–5894.
- Willie JT, Chemelli RM, Sinton CM, Tokita S, Williams SC, Kisanuki YY *et al* (2003). Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. *Neuron* **38**: 715–730.
- Yang B, Samson WK, Ferguson AV (2003). Excitatory effects of orexin-A on nucleus tractus solitarius neurons are mediated by phospholipase C and protein kinase C. *J Neurosci* **23**: 6215–6222.
- Zhou L, Ghee SM, Chan C, Lin L, Cameron MD, Kenny PJ *et al* (2011). Orexin-1 receptor mediation of cocaine-seeking in male and female rats. *J Pharmacol Exp Ther* **340**: 801–809.